Who is sponsoring NCT06877286?

NCT06877286 is sponsored by Cuma Bulent Gul.

What drugs are being tested in NCT06877286?

Interventions in NCT06877286: Sirtuin-1 Level Measurement.

What condition does NCT06877286 study?

NCT06877286 studies Chronic Kidney Disease, Hemodialysis, Anemia in End Stage Renal Disease, Erythropoietin.

Is NCT06877286 still recruiting?

NCT06877286 is currently completed. Last updated 19 March 2025.

Last reviewed 2025-03-19 · How we verify

NCT06877286

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.

Completed Last updated 19 March 2025

What this trial tests

trial testing Sirtuin-1 Level Measurement in Chronic Kidney Disease in 391 participants. Completed in 15 October 2021.

Timeline

1 August 2020

Primary endpoint
30 March 2021

15 October 2021

Quick facts

Lead sponsor	Cuma Bulent Gul
Status	Completed
Study type	OBSERVATIONAL
Enrollment	391
Start date	1 August 2020
Primary completion	30 March 2021
Estimated completion	15 October 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Sirtuin-1 Level Measurement

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Hemodialysis — all drugs for Hemodialysis →
Anemia in End Stage Renal Disease — all drugs for Anemia in End Stage Renal Disease →
Erythropoietin — all drugs for Erythropoietin →

Sponsor

Cuma Bulent Gul

Who can join

18 and older, any sex, with Chronic Kidney Disease or Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the relationship between Sirtuin-1 (SIRT1) levels and erythropoietin resistance in hemodialysis patients. The study aims to determine whether low SIRT1 levels contribute to EPO resistance and to explore the potential mechanisms involved. Blood samples and clinical data from hemodialysis patients will be analyzed to evaluate this relationship.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Low sirtuin-1 levels are linked to erythropoietin resistance in hemodialysis patients.
Hekimgil E, Gul CB. · · 2025 · PMID 40545983 · DOI 10.1080/0886022x.2025.2520909

Verify or expand the search:

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06877286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cuma Bulent Gul
Last refreshed: 19 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06877286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing